IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Artificial Intelligence Technology In Vaccine Development

[1]Name of 1st Author: Dr.P.Narayana Raju

[2]Name of 2nd Author: P.Sravanthi

[3]Name of 3rd Author: M.Ajay Ratnam

[4]Name of 4thAuthor: B.V.S.H Manish

[5]Name of 5th Author: Kunapam Vivek

[1]Designation of 1st Author: Professor
[2]Designation of 2nd Author: Assistant Professor
[3]Designation of 3rd Author: Assistant Professor
[4]Designation of 4th Author: Student pursuing B. pharm 4th year
[5]Designation of 5th Author: Student pursuing B. pharm 4th year

[1,2,3,4,5]Name of Department of Author: Department of Pharmaceutics
[1,2,3,4,5]Name of organization of Author, City, Country: Sri Vasavi Institute Of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh

Abstract: Artificial intelligence has become deeply embedded in modern health systems and is reshaping how pandemics are monitored, anticipated, and controlled. By combining machine learning, advanced analytics, and large-scale data integration, AI supports real-time epidemiological modeling, informs public health decision-making, and shortens the timelines for vaccine discovery and development. AI-based models, including extensions of SIR and SIS frameworks, help forecast transmission dynamics, allocate vaccines efficiently, and evaluate the likely impact of interventions on different populations, including low- and middle-income countries. This review outlines how AI contributes to epidemic modeling, vaccine target identification, vaccine design and formulation, clinical and preclinical evaluation, and surveillance, and it also considers applications in cancer immunotherapy and drug discovery. The article further highlights practical, ethical, and implementation issues and emphasizes the need for responsible and strategic integration of AI to strengthen preparedness for future global health threats.

Index Terms - machine learning techniques, epidemiological modeling, vaccine development, cancer, and immunotherapy.

I. INTRODUCTION

Recent outbreaks of emerging and re-emerging viral infections have underscored the vulnerability of global health systems to rapidly spreading pathogens. Mpox (formerly monkeypox), a zoonotic orthopoxvirus with a double-stranded DNA genome, has produced recurrent epidemics in recent years, particularly associated with clade IIb. Historically, the Democratic Republic of the Congo has reported a substantial share of cases, but the disease has increasingly appeared in other regions, creating new clinical and public health concerns. These events highlight the need for faster tools to characterise transmission, identify high-risk groups, and develop effective vaccines and immunot herapeutics, areas in which AI technologies are beginning to play a significant role.

Role of AI in Identifying Vaccine Targets:

The first critical step in rational vaccine design is the selection of antigens capable of eliciting a protective immune response. Traditional workflows rely on physical isolation of proteins from pathogens, iterative in vitro and in vivo testing, and extensive laboratory optimisation, all of which are time and resource intensive. AI-based approaches allow researchers to scan large genomic, proteomic, and structural datasets to prioritise candidate antigens much more efficiently.

Machine learning methods, including supervised and unsupervised models, can predict B- and T-cell epitopes, identify conserved regions across pathogen strains, and analyse three-dimensional protein structures to infer immunogenicity. Algorithms such as Random Forest and Support Vector Machines can process viral sequence data, for example from SARS-CoV-2, to estimate which peptide segments are most likely to bind MHC molecules and drive robust protective immunity. These in silico predictions guide experimental validation and help narrow down the number of targets that need to be tested in wet-lab systems, thereby accelerating early vaccine research [1]

AI in Cancer Vaccine and Immunotherapy Development

Cancer immunotherapy has transformed oncology but remains challenged by tumour heterogeneity, complex microenvironments, and diverse immune escape mechanisms. AI tools are increasingly being used to integrate multi-omics datasets, digital pathology, and single-cell sequencing to disentangle these complexities. By learning patterns within these high-dimensional data, AI systems can identify new immune targets and support the design of personalised therapeutic strategies.

A particularly important application is the prediction of tumour-specific neoantigens, which arise from somatic mutations and are absent from normal tissues. Deep learning models trained on patient-derived sequence and immune peptidomics data can estimate which mutant peptides will be efficiently presented by MHC molecules and recognised by CD8+ T cells. This capability enables the development of custom cancer vaccines tailored to each patient's mutational landscape and immune profile, supporting a precision medicine approach to oncology.[2]



Use of AI in Vaccine Development

Vaccine development is a cornerstone of infectious disease control but often requires many years of preclinical and clinical work and substantial financial investment. AI has emerged as a powerful set of tools to improve the speed, accuracy, and cost-effectiveness of this process. Across the vaccine pipeline, from target selection to formulation and clinical testing, AI-driven models help to reduce trial-and-error and guide evidence-based decision-making.

In early discovery, AI systems process genomic and structural information to select promising antigens, while in later stages they support optimisation of formulations, dosing regimens, and population-level deployment strategies. During rapidly evolving situations such as the COVID-19 pandemic, these capabilities allow candidate vaccines to be prioritised, refined, and evaluated more quickly than would be possible using conventional methods alone.[3]

Acceleration of Vaccine Candidate Identification

One of the clearest contributions of AI is the rapid identification of viable vaccine candidates from large biological datasets. Deep learning and other machine learning techniques can mine pathogen genomes and proteomes to detect motifs, domains, and structural features associated with strong immune responses. This replaces much of the slow empirical screening typically required to find suitable targets.

By modelling the relationship between sequence variation and immunogenicity, AI can rank candidate antigens and focus experimental resources on proteins with the highest predicted potential. In the context of emerging infections such as COVID-19, this prioritisation has been crucial for compressing timelines from pathogen identification to first-in-human trials.[4]

AI in Preclinical and Clinical Vaccine Research

AI does not only reshape the discovery phase; it also influences preclinical and clinical evaluation. In silico models can simulate host–pathogen and host–vaccine interactions, estimate potential adverse events, and forecast immune response profiles for different formulations or schedules before they enter extensive animal or human testing. Such predictive modelling supports better trial design and can reduce the number of unsuccessful candidates progressing into costly late-stage studies.

During clinical trials, AI tools are used to integrate multivariate patient data, including demographics, comorbidities, laboratory values, and immunological markers, to provide near real-time assessment of safety and efficacy signals. Machine learning algorithms can detect subtle patterns that may indicate emerging side effects, help refine dosing strategies, and identify subgroups more or less likely to benefit from a given vaccine, enabling more personalised and adaptive trial approaches.[5]

AI for Vaccine Formulation Optimisation

Optimising vaccine composition involves selecting antigens, adjuvants, stabilisers, and delivery platforms in combinations that maximise immunogenicity while minimising toxicity and logistical constraints. AI systems can model the complex relationships among these formulation variables and predict how different combinations will influence immune responses and stability profiles.

By virtually screening a large design space of possible components and concentrations, AI can highlight a small set of promising formulations to test experimentally. For example, models can simulate the impact of different adjuvants or nanoparticle carriers on antigen presentation, cytokine induction, and durability of protection, thereby guiding the development of formulations that are both effective and suitable for large-scale deployment.[6]

Machine Learning Methods and Algorithms in Drug Design

In small-molecule drug discovery, a central challenge is to improve lead compounds when only limited biological data are available. Classical chemo informatics representations, originally developed for computer-readable storage and querying, are now combined with modern machine learning algorithms to enable property prediction, virtual screening, and lead optimisation.

Standard techniques such as random forests and relatively simple neural networks have been shown to extract meaningful structure–activity relationships from datasets containing only a few hundred compounds. More advanced approaches, including one-shot or few-shot learning, exploit information from related tasks to construct distance metrics over chemical space, allowing accurate predictions even when training data are sparse. Cross-validation is widely used to evaluate these models, because it provides robust performance estimates and supports model selection for specific predictive tasks. Despite the success of deep learning in many applications, these architectures can be difficult to train in low-data

regimes and may require careful design to avoid overfitting, so the choice of algorithm must be tailored to the available data and objectives. [7].

AI in COVID-19 Drug Discovery

AI-assisted drug discovery has expanded quickly in response to the need for therapies against COVID-19 and other emerging infections. Machine learning and deep learning tools are used to screen very large compound libraries, prioritise molecules for in vitro testing, and support drug repurposing by identifying approved agents with potential antiviral activity. These methods help estimate efficacy, toxicity, and likely resistance profiles, thereby reducing the number of compounds that must be evaluated experimentally.[8]

Workflows for AI-driven COVID-19 drug discovery integrate techniques such as neural networks, homology modelling, protein structure prediction, and sequence-based representations like SMILES, often combined with recurrent models such as LSTM networks. Docking scores from tools like AutoDock Vina and toxicity predictions from platforms including DeepTox, LimTox, Tox21, and admetSAR are incorporated to refine lead selection. Although AI has not yet fully solved COVID-19 drug development, these approaches have demonstrated the potential to shorten development cycles and improve the quality of candidate molecules.[9]

Ligand-based models focus on chemical features of small molecules, while structure-based models incorporate information about viral or host protein targets; both strategies can be enriched with text- and knowledge-mining to guide hypothesis generation. Deep learning and methods such as generative topographic mapping have been applied to identify novel direct-acting antivirals and to support systematic repurposing efforts. However, progress is constrained by limited high-quality data for a new pathogen, unequal access to computing resources, and incomplete understanding of viral biology, which together can limit model generalisability and reliability.[10][11]



AI for Epidemiological Inference

During the initial phase of an outbreak, rapid estimation of key epidemiological parameters such as transmission rates, generation intervals, fatality ratios, and heterogeneity in spreading events is essential. Conventional observational studies, including case–control designs and cohort analyses, often provide incomplete or biased pictures of transmission because of underreporting, censoring, and irregular data collection. Individuals may also have complex contact patterns and asymptomatic infections that are not captured by routine surveillance, further complicating inference.

Bayesian data augmentation frameworks have been used to reconstruct unobserved infection chains and improve parameter estimation in the presence of missing data. AI and modern variational inference techniques, including approaches based on normalising flows, make these models more scalable and computationally efficient by reformulating the problem as optimisation rather than pure sampling. This allows timely, accurate inference even when decisions must be made rapidly, and it supports integration

of diverse data sources such as mobility, genomic, and clinical datasets into unified epidemic models.[12][13][14]

Conclusion:

AI is reshaping multiple dimensions of pharmaceutical and vaccine science, from basic discovery through to clinical deployment and drug delivery. In pharmacokinetics and pharmacodynamics, AI-driven models can estimate key parameters, simulate drug distribution and clearance, and optimise dosing strategies, with the potential to reduce reliance on animal experiments and large human trials. In formulation and manufacturing, computational pharmaceutics guided by AI and big data enables more efficient, quality-focused development of both small-molecule products and complex biologics, including vaccines.

By improving prediction, optimisation, and personalisation across the drug and vaccine pipeline, AI can enhance therapeutic efficacy, reduce adverse effects, and support more resilient health systems. Continued work is needed to address challenges around data quality, bias, interpretability, regulation, and ethical deployment, but the trajectory points towards an AI-enabled pharmaceutical ecosystem that advances from industry 4.0 to a more integrated, intelligent era 5.

ACKNOWLEDGMENT

I would like to express my sincere gratitude to my guide and mentors for their continuous support, encouragement, and valuable guidance throughout the completion of this work. I am also thankful to my faculty members, friends, and colleagues for their constructive suggestions and cooperation. Finally, I extend my heartfelt appreciation to my family for their constant motivation and understanding, which helped me accomplish this task successfully.

II. REFERENCES

[1] 1.Ankomah AA, Moa A, Chughtai AA. The long road of pandemic vaccine 449 development to rollout: a systematic review on the lessons learnt from the 2009 H1N1 450 influenza pandemic. American Journal of Infection Control. 2022;50(7):735-742. 451 https://doi.org/10.1016/j.ajic.2022.01.026

2 .Artificial intelligence and machine learning in the development of vaccines and immunotherapeuticsElhoucine Elfatimi1 , Yassir Lekbach1 , Swayam Prakash1 and Lbachir BenMohamed1,2,3,4 *

3.Rajkomar A, Dean J, Kohane I. Machine learning in medicine. New England Journal of Medicine. 2019; 380(14):1347-58.

4.Deo RC. Machine learning in medicine. Circulation. 2015; 132(20):1920- 30

5.Wang Y, Seo B, Wang B, Zamel N, Jiao K, Adroher XC. Fundamentals, materials, and machine learning of polymer electrolyte membrane fuel cell technology. Energy and AI. 2020:100014. 46. Singh A, Thakur N, Sharma A, editors. A review of supervised machine learning algorithms. 2016 3rd International Conference on Computing for Sustainable Global Development (INDIACom); 2016: Ieee.

6.Lloyd S, Mohseni M, Rebentrost P. Quantum algorithms for supervised and unsupervised machine learning. arXiv preprint arXiv:13070411. 2013.

7.Chayna Sarkar 1 , Biswadeep Das 2,* , Vikram Singh Rawat 3 , Julie Birdie Wahlang 1 , Arvind Nongpiur4 ,IadarilangTiewsoh5 , Nari M. Lyngdoh 6 , Debasmita Das 7 , Manjunath Bidarolli 2 and Hannah Theresa Sony 2

8.Swayamsiddha, S.; Prashant, K.; Shaw, D.; Mohanty, C. The prospective of Artificial Intelligence in COVID-19 Pandemic. Health Technol. 2021, 11, 1311–1320. [CrossRef]

9. Liu, Z.; Shi, Y.; Lin, Y.; Yang, Y. Intelligent Medicine and Beyond. KexueTongbao 2023, 68, 1165–1181. [CrossRef

10.. Floresta, G.; Zagni, C.; Gentile, D.; Patamia, V.; Rescifina, A. Artificial Intelligence Technologies for COVID-19 De Novo Drug Design. Int. J. Mol. Sci. 2022, 23, 3261. [CrossRef]

11.. Wang, L.; Zhang, Y.; Wang, D.; Tong, X.; Liu, T.; Zhang, S.; Huang, J.; Zhang, L.; Chen, L.; Fan, H.; et al. Artificial Intelligence for COVID-19: A Systematic Review. Front. Med. 2021, 8, 704256. [CrossRef] [PubMed]

12. Muratov, E.N.; Amaro, R.; Andrade, C.H.; Brown, N.; Ekins, S.; Fourches, D.; Isayev, O.; Kozakov, D.; Medina-Franco, J.L.; Merz, K.M.; et al. A critical overview of computational approaches employed for COVID-19 drug discovery. Chem. Soc. Rev. 2021, 50, 9121–9151. [CrossRef] [PubMed]

13. Gurung, A.B.; Ali, M.A.; Lee, J.; Farah, M.A.; Al-Anazi, K.M. An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19. BioMed Res. Int. 2021, 2021, 8853056. [CrossRef] [PubMed] 36. Kumar, A.; Gupta, P.K.; Srivastava, A. A review of modern technologies for tackling COVID-19 pandemic. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 569–573. [CrossRef] [PubMed] 37. Monteleone, S.; Kellici, T.F.; Southey, M.; Bodkin, M.J.; Heifetz, A. Fighting COVID-19 with Artificial Intelligence. Methods Mol. Biol. 2021, 2390, 103–112. [CrossRef]

14.Kraemer, M., Tsui, J., Chang, S., Lytras, S., Khurana, M., Vanderslott, S., Bajaj, S., Scheidwasser, N., Curran-Sebastian, J., Semenova, E., Zhang, M., Unwin, H. J. T., Watson, O., Mills, C., Dasgupta, A., Ferretti, L., Scarpino, S., Koua, E., Morgan, O., ... Bhatt, S. (2025). Artificial intelligence for modelling infectious disease epidemics. Nature, 638(8051), 623–635. Article eadp7977. https://doi.org/10.1038/s41586-024-08564-w